Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031444 | 0.84 | LMNA (0.35) | — | |
| SCHEMBL1661519 | 0.80 | UGT2B7 (0.39) | — | |
| SCHEMBL1662054 | 0.80 | ADRB2 (0.35) | — | |
| SCHEMBL1661088 | 0.80 | ADRB2 (0.35) | — | |
| SCHEMBL1661090 | 0.80 | ADRB2 (0.35) | — | |
| SCHEMBL3454007 | 0.76 | TRPV4 (0.31) | TRPV4KIF11 | |
| SCHEMBL1067649 | 0.76 | TRPV4 (0.31) | TRPV4KIF11 | |
| SCHEMBL2015398 | 0.76 | ABCB11 (0.41) | — | |
| SCHEMBL1069252 | 0.74 | TRPV4 (0.37) | TRPV4 | |
| SCHEMBL1069528 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024068976-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2024-04-04 | — | — | WO | claimed |
| EP-4345101-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2024-04-03 | — | — | EP | claimed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | claimed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | claimed |
| EP-3215500-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | claimed |
| WO-2016073420-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | claimed |
| WO-2024068976-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2024-04-04 | — | — | WO | disclosed |
| EP-4345101-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2024-04-03 | — | — | EP | disclosed |
| EP-3893645-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020123674-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-06-18 | — | — | WO | disclosed |
| CN-105263929-B | 3-Pyrimidin-4-yl-oxazolidin-2-one compounds as mutant IDH inhibitors | 诺华股份有限公司 | 2018-08-28 | — | — | CN | disclosed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | disclosed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | disclosed |
| CN-105745214-A | Tricyclic piperidine compounds | 埃科特莱茵药品有限公司 | 2016-07-06 | — | — | CN | disclosed |
| WO-2016073420-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
| CN-105263929-A | 3-Pyrimidin-4-yl-oxazolidin-2-one compounds as mutant IDH inhibitors | NOVARTIS AG | 2016-01-20 | — | — | CN | disclosed |
| WO-2015075023-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | disclosed |
| CN-103958506-A | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG | 2014-07-30 | — | — | CN | disclosed |
| WO-2011006886-A2 | AZOLE COMPOUNDS CARRYING A SULFUR SUBSTITUENT XIV | BASF SE (DE) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010149758-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | TRPV4 1844/4885KIF11 3512/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | TRPV4 1844/4885KIF11 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.